Drug Trial Radar · NCT07664956
Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- Christiana Care Health ServicesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.
Conditions
- Minimally Invasive Surgical Procedures
- Abnormal Uterine Bleeding, Unspecified
- Adenomyosis of Uterus
- Fibroid Uterus
- Chronic Pelvic Pain
- Endometriosis
- Menorrhagia
- Endometritis
- Adnexal Diseases
Interventions
CyclobenzaprineDrug
5mg cyclobenzaprine q8hr for one week postoperatively after minimally invasive hysterectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual Analog Scale (VAS) Pain Score on Post Op Day 3Time frame: 3 days postoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ChristianaCare Health System
Newark, Delaware · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.